UNDERSTANDING IGA NEPHROPATHY

ABOUT THE DISEASE

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis in the Western world. It is a serious autoimmune, chronic inflammatory, progressive disease that leads to decreasing kidney function over the course of 10 to 20 years.

Read More

THE NEFIGARD CLINICAL STUDY

Calliditas Therapeutics is sponsoring the NefIgArd clinical study, a randomized double-blind and placebo-controlled Phase 3 study for IgA nephropathy. We will enroll up to 450 participants in the NefIgArd study.

Read More

FREQUENTLY ASKED QUESTIONS

Read More